Michael Boyd, MD
Pulmonary Disease · Charlottesville, VANPI 1487839270
Payments from drug & device makers
Across 351 payments — averaging $13.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$751
- Mylan Specialty L.p.$380
- United Therapeutics Corporation$325
- Sunovion Pharmaceuticals Inc.$278
- Boehringer Ingelheim$194
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,51897%
- Education$1293%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 122 | $1,064 |
| AstraZeneca | 43 | $751 |
| Mylan Specialty L.p. | 18 | $380 |
| United Therapeutics Corporation | 29 | $325 |
| Sunovion Pharmaceuticals Inc. | 25 | $278 |
| Boehringer Ingelheim | 12 | $194 |
| Philips North America LLC | 10 | $177 |
| Mallinckrodt Enterprises LLC | 9 | $171 |
| Mallinckrodt Hospital Products Inc. | 10 | $164 |
| Sanofi | 9 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $116 |
| Actelion Pharmaceuticals US, Inc. | 6 | $104 |
| Johnson & Johnson | 7 | $96 |
| AbbVie(2 entities) | 6 | $86 |
| Regeneron Healthcare Solutions, Inc. | 6 | $76 |
| Grifols USA, LLC | 3 | $63 |
| Electromed, Inc. | 4 | $62 |
| ANI Pharmaceuticals, Inc. | 4 | $52 |
| Novo Nordisk | 2 | $51 |
| Merck | 4 | $49 |
| Pfizer | 3 | $47 |
| CSL Behring | 2 | $41 |
| Novartis | 2 | $31 |
| Genentech USA, Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Biogen | 1 | $23 |
| Resmed Corp | 2 | $22 |
| Insmed, Inc. | 1 | $16 |
| Amgen | 1 | $12 |
How this compares
$4,647 in reported general payments places this provider in the 55th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Charlottesville
- Hannah MannemCharlottesville$326K
- Imre NothCharlottesville$261K
- Ellen VolkerCharlottesville$177K
- Numaan MalikCharlottesville$176K
- Tessy PaulCharlottesville$158K
- Andrew MihalekCharlottesville$91K
- Alexandra KadlCharlottesville$38K
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.